{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:51:32Z","timestamp":1784055092645,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.lungcan.2023.02.008","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:30:33Z","timestamp":1676431833000},"page":"166-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study"],"prefix":"10.1016","volume":"178","author":[{"given":"Keunchil","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua K.","family":"Sabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Haura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Reckamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Roshak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Millington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Thayu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.02.008_b0005","doi-asserted-by":"crossref","unstructured":"Moores SL, Chiu ML, Bushey BS, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res 2016;76(13):3942-53. DOI: 10.1158\/0008-5472.CAN-15-2833.","DOI":"10.1158\/0008-5472.CAN-15-2833"},{"key":"10.1016\/j.lungcan.2023.02.008_b0010","doi-asserted-by":"crossref","unstructured":"Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR\/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte\/Macrophage Trogocytosis. Mol Cancer Ther 2020;19(10):2044-2056. DOI: 10.1158\/1535-7163.MCT-20-0071.","DOI":"10.1158\/1535-7163.MCT-20-0071"},{"key":"10.1016\/j.lungcan.2023.02.008_b0015","doi-asserted-by":"crossref","unstructured":"Yun J, Lee SH, Kim SY, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov 2020;10(8):1194-1209. DOI: 10.1158\/2159-8290.CD-20-0116.","DOI":"10.1158\/2159-8290.CD-20-0116"},{"key":"10.1016\/j.lungcan.2023.02.008_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9009","article-title":"JNJ-61186372 (JNJ-372), an EGFR-cMet Bispecific Antibody, in EGFR-Driven Advanced Non-small Cell Lung Cancer (NSCLC)","author":"Haura","year":"201937159009","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.lungcan.2023.02.008_b0025","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2023.02.008_b0030","doi-asserted-by":"crossref","unstructured":"Spira A, Krebs M, Cho BC, et al. Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS. J Thorac Oncol 2021;16(10 Supplement):S874-875. DOI: 10.1016\/j.jtho.2021.08.084.","DOI":"10.1016\/j.jtho.2021.08.084"},{"key":"10.1016\/j.lungcan.2023.02.008_b0035","unstructured":"RYBREVANT\u00ae (amivantamab) [package insert]. Horsham, PA: Janssen Biotech, Inc. 2021. Accessed at: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/RYBREVANT-pi.pdf."},{"key":"10.1016\/j.lungcan.2023.02.008_b0040","unstructured":"RYBREVANT (amivantamab) [European public assessment report]. Janssen-Cilag International N.V. 2022. Accessed at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybrevant-epar-product-information_en.pdf."},{"issue":"3","key":"10.1016\/j.lungcan.2023.02.008_b0045","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.21873\/anticanres.14062","article-title":"Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lungcan.2023.02.008_b0050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/TCRM.S204909","article-title":"The Importance of Early Identification of Infusion-related Reactions to Monoclonal Antibodies","volume":"15","author":"Caceres","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.lungcan.2023.02.008_b0055","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. November 27, 2017. Accessed at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"10.1016\/j.lungcan.2023.02.008_b0060","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. June 14, 2010. Accessed at: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf."},{"key":"10.1016\/j.lungcan.2023.02.008_fur1","doi-asserted-by":"crossref","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200\/JCO.21.00662. Epub 2021 Aug 2. PMID: 34339292; PMCID: PMC8791812.","DOI":"10.1200\/JCO.21.00662"},{"key":"10.1016\/j.lungcan.2023.02.008_fur2","doi-asserted-by":"crossref","unstructured":"Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N. Amivantamab Compared With Real-world Therapies in Patients With Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Progressed After Platinum-based Chemotherapy. Lung Cancer. 2022 Jun;168:74-82. doi: 10.1016\/j.lungcan.2022.03.005. Epub 2022 Mar 8. PMID: 35597172.","DOI":"10.1016\/j.lungcan.2022.03.005"},{"key":"10.1016\/j.lungcan.2023.02.008_fur3","doi-asserted-by":"crossref","unstructured":"Jatkoe T, Wang S, Odegaard JI, Velasco Roth AM, Osgood D, Martinez G, Lucas P, Curtin JC, Karkera J. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab. J Mol Diagn. 2022 Nov;24(11):1181-1188. doi: 10.1016\/j.jmoldx.2022.07.003. Epub 2022 Aug 10. PMID: 35963523.","DOI":"10.1016\/j.jmoldx.2022.07.003"},{"key":"10.1016\/j.lungcan.2023.02.008_fur4","doi-asserted-by":"crossref","unstructured":"Chouaid C, Bosquet L, Girard N, Kron A, Scheffler M, Griesinger F, Sebastian M, Trigo J, Viteri S, Knott C, Rodrigues B, Rahhali N, Cabrieto J, Diels J, Perualila NJ, Schioppa CA, Sermon J, Toueg R, Erdmann N, Mielke J, Nematian-Samani M, Martin-Fernandez C, Pfaira I, Li T, Mahadevia P, Wolf J. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Adv Ther. 2023 Jan 18. doi: 10.1007\/s12325-022-02408-7. Epub ahead of print. PMID: 36652175.","DOI":"10.1007\/s12325-022-02408-7"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:06:25Z","timestamp":1759237585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":16,"alternative-id":["S0169500223000697"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.02.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Janssen Research and Development LLC. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}